Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “outperform” rating reiterated by equities research analysts at Cowen and Company in a report issued on Wednesday. They currently have a $190.00 target price on the specialty pharmaceutical company’s stock. Cowen and Company’s price objective indicates a potential upside of 32.96% from the company’s previous close.

Other research analysts have also issued research reports about the company. Leerink Swann set a $179.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, April 27th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, April 27th. Zacks Investment Research raised Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 price target for the company in a research report on Monday, May 15th. Vetr raised Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 price target for the company in a research report on Tuesday, June 6th. Finally, Royal Bank Of Canada set a $210.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Tuesday, June 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $183.26.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 6.17% during midday trading on Wednesday, reaching $142.90. The company had a trading volume of 1,992,004 shares. The stock has a market capitalization of $8.58 billion, a price-to-earnings ratio of 21.59 and a beta of 1.10. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The company has a 50-day moving average price of $155.76 and a 200-day moving average price of $145.81.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.85 by $0.13. The business had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the previous year, the company earned $2.67 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post $11.02 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-nasdaqjazz-given-outperform-rating-at-cowen-and-company/1466763.html.

In related news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $152.98, for a total value of $30,596.00. Following the sale, the executive vice president now owns 22,623 shares in the company, valued at approximately $3,460,866.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Suzanne Sawochka Hooper sold 420 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $160.00, for a total value of $67,200.00. The disclosure for this sale can be found here. Insiders sold a total of 40,600 shares of company stock worth $6,245,820 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the company. US Bancorp DE increased its stake in Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares during the last quarter. Gargoyle Investment Advisor L.L.C. bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at $206,000. Janney Montgomery Scott LLC bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at $211,000. Finally, Brighton Jones LLC bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at $213,000. Institutional investors own 86.43% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.